Google AI

Yicura BioMed Advances Dual Capital and Industrial Strategy: Completes First Closing of Series B Financing Led by Gobi Partners

Advancing Core Product ICVAX® for HIV & Immunotherapy Pipeline for Cancers

HONG KONG SAR – Media OutReach Newswire – 13 November 2026 – Yicura BioMed ("Yicura"), a clinical-stage immunotherapy company based in the Hong Kong Science Park developing medicines for infectious diseases, cancers, and inflammatory diseases, is pleased to announce today the first closing of its Series B financing led by Gobi Partners, with participation from a number of strategic investors from Wuxi and institutional investors from Hong Kong.

hacklink makrobetesim espagnemarsbahisjojobetnon gamstopgamstop.orgBetimgrandpashabet resmi girişhttps://na-samom-dele.ru/казино водкаhttps://monteon.ru/seo ajansıyurtdışı turseo danışmanlığıjojobet